Innovations and development in Neopharm Bulgaria Ltd

Neopharm Bulgaria Ltd is one of the leading companies in food additive production the bigger part of which are developed by us or together with scientific organizations. This project will be implemented in partnership with Microbiology Institute to BAS. This is a hi-tech scientific research project and requires specific knowledge, skills and experience. The strain characteristics as well as the isolation methodology and the possible end products are new at worldwide level. The aim is to isolate at least one strain of human origin that will change the proportion Firmicutes/Bacteroidetes – the main types of bacteria dominating our microbiome. If this research turns to be successful we shall have a „natural“ probiotic strain with described characteristics which is possible to be added to different products after some additional experimental work. It is expected that this will have impact on some metabolic illnesses. The project as well as its end results are part of the ISIS thematic area „Healthy life and biotechnology“. There will be carried out two activities – science and research and creation and testing of prototypes. They are divided into stages where the results from one stage are the basis for the next one. The probiotic strain will be isolated, genetically typified and there will be determined parameters for its future industrial production. There will be ensured stable jobs for 22 experts in Neopharm and 7 with the Partner. The experts from Neopharm will participate in specialized researches and will gain significant experience in performing scientific activities. Most of the activities will be carried out in the specialized laboratory premises of the partner because of the requested specifics, conditions and equipment. There will be used materials and consumables for the msny tests and analysis. The intellectual property will be protected by a patent of invention At the end of the project we shall have a prototype and technology, reaching TRL6

Comments
Leave a comment

Overview

Status Closed (completion date)
Start date 16 Nov, 2018
End date 15 Apr, 2021
Contract date 16 Nov, 2018
View in UMIS

Financial information

Total cost 436,038.00
Grant 320,514.70
Self finance 115,523.30
Total paid 258,885.20
EU participation percent 85.0%

Location